PPT-MEK Inhibitors and their potential role in relapsed NSCLC

Ranee Mehra MD Fox Chase Cancer Center Philadelphia PA Disclosures Consulting Novartis Bristol Myers Squib Spouse is employee of GSK Acknowledgment J Weiss RasRafMEKERK12 MAP kinase. With a Short First Remission:. How Aggressive Should We Be?. Carla Casulo, MD. Wilmot Cancer Institute. University of Rochester Medical Center. Rochester, New York . Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies. 5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN 322 BCH. Exp. (8). In this experiment, we will continue to study . acid phosphatase . kinetics.. Objectives. To . study the effect of inhibitors on the rate of an enzymatic reaction.. To . determine the type of inhibition of acid phosphatase by inorganic phosphate and sodium fluoride. . Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. Inhibitors. anodic inhibitors. : . p. hosphates. s. ilicate . c. ompounds. . Cathodic inhibitors. poly-p. hosphates. . Ca(HCO3)2. methylamino-phosphate. (c). . mixed anodic and cathodic inhibitors. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. CDK 4/6 Inhibitors in Breast Cancer Expert Perspectives on New Data Faculty Javier Cortes, MD, PhD Head Breast Cancer Program Oncology Department Ramon y Cajal University Hospital Madrid, Spain Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. 3aDuzuaBaebolonekayewananzembfabdigyimalaanwoanaduzuatiabayseyeamaabiemkbbaliemNyamenlekalabadonuabDuzuawkyyewadalzonlenlnwode-biebialamlyelaanwoa4aKziykolaynwuyekmwuamrazonlenllemgbanebDuzuatiaGyihov Medication Teaching The Center for Breast Cancer Mass General Cancer Center 2 Topics to Discuss • What are Aromatase Inhibitors? How do they work in the body? • Reasons for taking an Aromatase I fli:GFP. ) Casper Zebrafish Embryos. . Kelly . Cristine. de Sousa Pontes,. 1. . Arwin. Groenewoud,. 2. . Jinfeng. Cao,. 1,3 . Ewa. Snaar-Jagalska,. 2. Martine J. Jager. 1. 1. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .